Radiopharm (ASX: RAD) Secures Supply Deal with Cyclotek for Prostate Cancer Trial

June 24, 2025 01:06 PM AEST | By Aditi Sarkar

Google News:

Radiopharm (ASX: RAD) Secures Supply Deal with Cyclotek for Prostate Cancer Trial — Image source: Company Update

Recent News

Lithium Royalty Corp. Renews Normal Course Issuer Bid

Coeur Announces Second Quarter 2025 Earnings Call

Teva Recognized Among TIME and Statista’s 2025 World’s Most Sustainabl...

Mondelēz International Joins the 100+ Accelerator To Help Advance More...

Highlights

Radiopharm and Cyclotek have signed a supply deal to advance RAD 402 for prostate cancer treatment.

RAD 402 to feature in the first company-sponsored prostate cancer study using Terbium-161 (¹⁶¹Tb).

Phase 1 clinical trial of RAD 402 is set to launch in Australia in 2H 2025.

¹⁶¹Tb offers potential advantages over ¹⁷⁷Lu through additional tumor-killing electrons.

Collaboration marks the final step before ethics submission and trial initiation.

Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX), a clinical-stage biopharmaceutical company developing innovative radiopharmaceutical therapies for cancer, has reached a major milestone in the development of its novel radiotherapeutic RAD 402 for prostate cancer. The company has entered into a supply agreement with Cyclotek, a major radiopharmaceutical manufacturer. Under the deal, Cyclotek will produce and supply doses of ¹⁶¹Tb-labeled RAD 402 in Australia.

Phase 1 Trial Set for 2H 2025

The agreement paves the way for Radiopharm to launch its Phase 1 clinical trial, anticipated to begin in the second half of 2025. RAD 402 is an anti-Kallikrein Related Peptidase 3 (KLK3) monoclonal antibody radiotherapeutic labelled with the radionuclide ¹⁶¹Tb, for fighting prostate cancer

Designed specifically for prostate cancer, RAD 402 targets KLK3, a biomarker with high expression in prostate tissue and minimal expression elsewhere, enhancing the precision and potential safety of the treatment.

The Phase 1 clinical trial will be the first company-sponsored prostate cancer study using ¹⁶¹Tb.

RAD 402 is uniquely radiolabelled with ¹⁶¹Tb, a next-generation radionuclide that offers enhanced therapeutic potential. Compared to conventional agents such as Lutetium-177 (¹⁷⁷Lu), ¹⁶¹Tb emits additional Auger and conversion electrons, which may improve tumor-killing efficacy.

Greg Santamaria, CEO of Cyclotek, shared his enthusiasm for the collaboration: “We are pleased to partner with Radiopharm to facilitate the development of their innovative radiotherapeutic, RAD 402. Our mission is to improve access to radiopharmaceuticals to enhance patient outcomes, and we look forward to supporting this important step toward market approval.”

Radiopharm Theranostics continues to expand its clinical pipeline, which includes one Phase 2 and three Phase 1 trials across multiple solid tumour types. The company is focused on bringing advanced radiopharmaceutical therapies to patients with high unmet medical needs.

Shares of RAD were trading at AUD 0.023 at the time of writing on 24 June 2025.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.